- SG$598.63m
- SG$517.05m
- SG$78.18m
- 80
- 31
- 90
- 78
Annual income statement for TalkMed, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 62.1 | 60.7 | 76.6 | 83.8 | 78.2 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 36.2 | 32.4 | 37.5 | 44.5 | 40.4 |
| Operating Profit | 25.9 | 28.4 | 39.1 | 39.3 | 37.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 24.8 | 27.3 | 36.8 | 37.8 | 49.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 18.5 | 21.4 | 29 | 29.4 | 42.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 22.8 | 25.1 | 30.5 | 32.2 | 43.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 22.8 | 25.1 | 30.5 | 32.2 | 43.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.018 | 0.018 | 0.023 | 0.025 | 0.031 |
| Dividends per Share | |||||
| Special Dividends per Share |